FNY Investment Advisers’s Biogen BIIB Stock Holding History

FNY Investment Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50	Closed	-$6K	–	975
2025 Q1	$6K	Buy	+50	New	+$7.15K	﹤0.01%	544
2022 Q1	–	Sell	-25	Closed	-$5K	–	745
2021 Q4	$5K	Buy	+25	New	+$6.43K	﹤0.01%	431
2019 Q3	–	Sell	-9	Closed	-$2K	–	897
2019 Q2	$2K	Buy	9 +1	+13%	+$231	﹤0.01%	815
2019 Q1	$1K	Buy	+8	New	+$2.52K	﹤0.01%	641

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FNY Investment Advisers's BIIB Position: Q4 2025 in Review

FNY Investment Advisers sold out of Biogen (BIIB) in Q4 2025, closing a stake of 13 shares — an estimated $1K sold.

FNY Investment Advisers first reported a position in BIIB in Q2 2018 and held it in 13 quarters. The position peaked at $1.22M in Q4 2020. 999 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

FNY Investment Advisers reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
FNY Investment Advisers sold 13 Biogen shares in Q4 2025, an estimated $1K.
FNY Investment Advisers first reported a position in Biogen in Q2 2018 and held it in 13 quarters.
FNY Investment Advisers's Biogen position peaked at $1.22M in Q4 2020.
999 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.